I could be argued that it would make most sense, if NNZ-2591 has successful results in all 4 current indications, for a well-resourced pharma to run concurrent Phase 3 trials. But from a risk-managing perspective, that might not be an attractive option for them.
Also, outside of those 4 indications, where does Acadia stand with NNZ-2591 in Rett and Fragile-X? Phase 2 or 3 trials are yet to be held and so are quite some years away from any FDA approval. Why would Acadia bother if, say, NNZ-2591 in PMS was approved in a few years’ time, setting off the ticking of the IRA clock on Acadia's in-licensed NNZ-2591 Rett and Fragile-X assets?
What does make sense to me is for Neuren to continue to proceed full steam ahead on Phase 3 in PMS as that just continues to add value. I think the big decision-making point wouldn’t come until the time of any NDA submission and, in the meantime, the IRA law might have been amended and/or Neuren might have already been acquired and it’s someone else’s decision to make!
- Forums
- ASX - By Stock
- Ann: Trading Halt
I could be argued that it would make most sense, if NNZ-2591 has...
-
- There are more pages in this discussion • 136 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.61 |
Change
-0.590(4.15%) |
Mkt cap ! $1.739B |
Open | High | Low | Value | Volume |
$13.88 | $13.91 | $13.29 | $13.29M | 982.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | $13.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.63 | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | 13.550 |
2 | 4497 | 13.530 |
1 | 3378 | 13.520 |
15 | 29080 | 13.500 |
1 | 3079 | 13.470 |
Price($) | Vol. | No. |
---|---|---|
13.630 | 1000 | 1 |
13.680 | 3079 | 1 |
13.700 | 1000 | 1 |
13.710 | 3079 | 1 |
13.740 | 3079 | 1 |
Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |